Organ-specific or personalized treatment for COVID-19: rationale, evidence, and potential candidates

Although extrapulmonary manifestations of coronavirus disease 2019 (COVID-19) are increasingly reported, no effective therapeutic strategy for these multisystemic complications is available due to a poor understanding of the pathophysiology of COVID-19 multiorgan involvement. In this study, differen...

Full description

Saved in:
Bibliographic Details
Published in:Functional & integrative genomics 2022-06, Vol.22 (3), p.429-433
Main Authors: Mousavi, Seyedeh Zahra, Rahmanian, Mojdeh, Sami, Ashkan
Format: Article
Language:English
Subjects:
Alveoli
Animal Genetics and Genomics
Biochemistry
Bioinformatics
Biomedical and Life Sciences
Cell Biology
Cell Line
Choroid plexus
Coronaviruses
COVID-19
COVID-19 - drug therapy
Drug development
Hepatocytes
Humans
Life Sciences
Microbial Genetics and Genomics
Organoids
Pathophysiology
Plant Genetics and Genomics
Pluripotency
Precision Medicine
Protein Interaction Maps
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Short Communication
Stem cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although extrapulmonary manifestations of coronavirus disease 2019 (COVID-19) are increasingly reported, no effective therapeutic strategy for these multisystemic complications is available due to a poor understanding of the pathophysiology of COVID-19 multiorgan involvement. In this study, differentially expressed genes (DEGs) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected extrapulmonary organs including human pluripotent stem cells (hPSCs)-derived liver organoids and choroid plexus organoids besides transformed lung alveolar (A549) cells were analyzed. First, pathway enrichment analysis was done to compare the underlying biological pathways enriched upon SARS-CoV-2 infection in different organs. Then, these lists of DEGs were used in a connectivity map (CMap)-based drug repurposing experiment. Also, protein–protein interaction (PPI) network analysis was done to compare the associated hub genes. The results revealed different biological pathways and genes responsible for SARS-CoV-2 multisystemic pathogenesis based on the organ involved that highlighted the need for considering organ-specific treatments or even personalized therapy. Besides, some FDA-approved drugs were proposed as the potential therapeutic candidates for each infected cell line.
ISSN:1438-793X
1438-7948
DOI:10.1007/s10142-022-00841-z